Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

Related Articles by Review for PubMed (Select 10168031)

1.
2.
3.

Sertraline. A pharmacoeconomic evaluation of its use in depression.

Davis R, Wilde MI.

Pharmacoeconomics. 1996 Oct;10(4):409-31. Review.

PMID:
10184609
4.

Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Wilde MI, Whittington R.

Pharmacoeconomics. 1995 Jul;8(1):62-81. Review.

PMID:
10155603
5.

A critical review of selected pharmacoeconomic analyses of antidepressant therapy.

Conner TM, Crismon ML, Still DJ.

Ann Pharmacother. 1999 Mar;33(3):364-72. Review.

PMID:
10200863
6.

Cost-effective treatment of depression with selective serotonin reuptake inhibitors.

Panzarino PJ Jr, Nash DB.

Am J Manag Care. 2001 Feb;7(2):173-84. Review.

7.

Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Guze BH.

Pharmacoeconomics. 1996 May;9(5):430-42. Review.

PMID:
10160255
8.

Economic comparisons of the pharmacotherapy of depression: an overview.

Crott R, Gilis P.

Acta Psychiatr Scand. 1998 Apr;97(4):241-52. Review.

PMID:
9570483
9.

Economic considerations in the prescribing of third-generation antidepressants.

Montgomery S, Doyle JJ, Stern L, McBurney CR.

Pharmacoeconomics. 2005;23(5):477-91. Review.

PMID:
15896099
10.

Side effects, dropouts from treatment and cost consequences.

Montgomery SA, Kasper S.

Int Clin Psychopharmacol. 1998 Feb;13 Suppl 2:S1-5. Review.

PMID:
9669192
11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Fluoxetine. A pharmacoeconomic review of its use in depression.

Wilde MI, Benfield P.

Pharmacoeconomics. 1998 May;13(5 Pt 1):543-61. Review.

PMID:
10180753
13.

Debits and credits in the management of depression.

Henry JA.

Br J Psychiatry Suppl. 1993 Jul;(20):33-9. Review.

PMID:
8352915
14.

The economics of selective serotonin reuptake inhibitors in depression: a critical review.

Frank L, Revicki DA, Sorensen SV, Shih YC.

CNS Drugs. 2001 Jan;15(1):59-83. Review.

PMID:
11465013
15.

Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions.

Sclar DA, Skaer TL, Robison LM, Stowers JK.

Depress Anxiety. 1998;8 Suppl 1:121-7. Review.

PMID:
9809224
16.

Treatment of depression--newer pharmacotherapies.

Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett R, Noël PH, Lawrence V, Lee S, Luther M, Ramirez G, Richardson WS, Stamm K.

Psychopharmacol Bull. 1998;34(4):409-795. Review.

PMID:
10513454
17.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
18.

The cost of depression in the elderly. Effects of drug therapy.

Hughes D, Morris S, McGuire A.

Drugs Aging. 1997 Jan;10(1):59-68. Review.

PMID:
9111708
19.

Severe depression: is there a best approach?

Sonawalla SB, Fava M.

CNS Drugs. 2001;15(10):765-76. Review.

PMID:
11602003
20.

Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.

Hensley PL, Nurnberg HG.

Pharmacoeconomics. 2001;19(10):973-82. Review.

PMID:
11735668
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk